Trial Profile
Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs CK 0801 (Primary)
- Indications Guillain-Barre syndrome
- Focus Adverse reactions
- Sponsors Cellenkos
- 03 Jan 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Jul 2021 Planned End Date changed from 1 Feb 2022 to 1 Feb 2027.
- 19 Jul 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2025.